Mark your calendars for the 23rd IMS Annual Meeting in Glasgow, Scotland.
The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical, and clinical aspects. This year’s program includes:
Four thematic sessions:
Newly Diagnosed Multiple Myeloma
How to Treat First Relapse
Blood-Based Technology for Diagnosis and Monitoring
Monitoring Immune System and Preventing Infections and Adverse Effects
Talks and symposia led by key opinion leaders in the myeloma community
Keynote addresses
Joint sessions with regulatory agencies and other organizations
The International Myeloma Society (IMS) is please to announce our “Best of IMS Series” a curated collection of the most significant insights and key breakthroughs from our annual meeting. This series of four webinars for our audiences in East Coast, West Coast, Europe, and Asia Pacific.
Practical Insights into and Translational Aspects of Novel Immune Therapies in Multiple Myeloma
October 12, 2026 - Vienna, Austria
This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
Not attending the DGHO Annual Meeting? Select the “On-demand Registration” option to receive access to the recording approximately 3 weeks post-meeting.
Learn about the IMS and Paula and Rodger Riney Foundation Translational Research Award
Learn about the IMS Career Development Award
Meet the recipients of the IMS Translational Research Award!
Meet the recipients of the IMS Career Development Award!
About Our Publications
As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
